Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2023-03-07 00:00:00 ET · period of report 2023-03-03 · accession 0001735276-23-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-07 | 2023-03-03 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $96.45 | +5,000 | 22.4K | +29% | +$482.2K |
| D | 2023-03-07 | 2023-03-03 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | S - Sale+OE | $200.00 | -18.1K | 4,345 | -81% | -$3.61M |
| DM | 2023-03-07 | 2023-03-03 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $0.00 | -5,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-03 | M | A | 2,500 | $96.45 | 19,917 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-03 | S | D | 18,072 | $200.00 | 4,345 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-03 | M | A | 2,500 | $96.45 | 22,417 | D | — | — | |
| 4 | Derivative | Performance Stock Option 2014 (right to buy) | 2023-03-03 | M | D | 2,500 | $0.00 | 0 | D | $96.45 · 2018-08-11 to 2024-12-17 | 2,500 Common Stock | |
| 5 | Derivative | Stock Option (right to buy) | 2023-03-03 | M | D | 2,500 | $0.00 | 0 | D | $96.45 · — to 2024-12-17 | 2,500 Common Stock | (F4) The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date, and were fully vested on December 17, 2018. |